# Soligenix Inc. (NASDAQ: SNGX) Highlights Encouraging Phase 3 Progress for HyBryte(TM) in Investment Webinar

* A focus during the webinar was the investigator-initiated study currently being conducted at the University of Pennsylvania under the leadership of Dr. Ellen Kim.
* Interim results show that among the first eight patients who completed 18 weeks of treatment, 75% demonstrated a greater than 50% reduction in disease severity.
* Soligenix anticipates top-line results from the phase 3 trial in the second half of 2026.

 In a recent webinar hosted by Allele Capital, Soligenix (NASDAQ: SNGX) executives Dr. Christopher Schaber and Dr. Christopher Pullion shared detailed updates on the company’s HyBryte(TM) (synthetic hypericin) clinical development (https://ibn.fm/dz7eO). The event offered an in-depth look at Soligenix’s ongoing confirmatory phase 3 trial for cutaneous T-cell lymphoma (“CTCL”), a rare non-Hodgkin’s lymphoma, and discussed promising data emerging from an investigator-initiated study conducted at the University of Pennsylvania. Soligenix, a late-stage biopharmaceutical company, is dedicated to developing and commercializing treatments for rare diseases and unmet medical needs, and HyBryte(TM) represents the company’s lead asset aimed at transforming the treatment landscape for CTCL.

 HyBryte(TM) is a topical therapy activated by visible light that is applied directly to cancerous lesions on the skin, primarily targeting early-stage mycosis fungoides, which account for nearly 90% of CTCL cases. According to Dr. Schaber, Soligenix chairman, president and CEO, CTCL affects approximately…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/soligenix-inc-nasdaq-sngx-highlights-encouraging-phase-3-progress-for-hybrytetm-in-investment-webinar/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/soligenix-s-hybryte-tm-shows-promise-in-ctcl-treatment/1e20ef79a63d75ad117a084d7b0ad517) 

 



[Reddit Post](https://www.reddit.com/r/newsramp/comments/1lqsj1l/soligenixs_hybrytetm_shows_promise_in_ctcl/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/257/3/blurSBLs.webp)